Table 5.
Major or CRNM bleeding events (ISTH) occurring from start of ablation up to 48 h after the end of the ablation procedure
| Total (N = 553), n (%) | Edoxaban (N = 375), n (%) | VKA (N = 178), n (%) | |
|---|---|---|---|
| Major or CRNM bleeding (ISTH) | 24 (4.3) | 17 (4.5) | 7 (3.9) |
| Heparin dose < median of treatment arma | 6 | 4 | |
| Heparin dose ≥ median of treatment arma | 11 | 3 | |
| Major bleeding (ISTH) | 10 (1.8) | 7 (1.9) | 3 (1.7) |
| Heparin dose < median of treatment arma | 2 | 1 | |
| Heparin dose ≥ median of treatment arma | 5 | 2 |
CRNM, clinically relevant non-major bleeding; ISTH, International Society on Thrombosis and Haemostasis.
a
Median heparin dose was 13 000 IU in edoxaban arm and 10 225 IU in VKA arm.